成人烟雾病按起病类型分层的搭桥手术结局
该回顾性全国人群队列研究纳入2008年1月1日至2020年12月31日诊断、随访至2021年12月31日的19700例成人烟雾病患者(出血型3194例、缺血型517例、无症状型15989例),比较搭桥手术与保守治疗的结局。出血型搭桥与死亡风险降低(AHR 0.50,95%CI 0.41-0.61,P<.001)和出血性卒中风险降低(AHR 0.36,95%CI 0.30-0.40,P<.001)相关;缺血型搭桥与缺血性卒中风险降低相关(AHR 0.55,95%CI 0.37-0.81,P=.002);无症状型搭桥与死亡风险降低(AHR 0.74,95%CI 0.66-0.84,P<.001)但出血性卒中风险增加(AHR 1.76,95%CI 1.56-2.00,P<.001)相关。作者认为应依据起病类型制定个体化管理策略。
要点
- 出血型烟雾病:搭桥手术与死亡风险降低相关(AHR 0.50,95%CI 0.41-0.61,P<.001),与出血性卒中风险降低相关(AHR 0.36,95%CI 0.30-0.40,P<.001)。
- 缺血型烟雾病:搭桥手术与缺血性卒中风险降低相关(AHR 0.55,95%CI 0.37-0.81,P=.002);仅直接搭桥与缺血性卒中风险降低相关(AHR 0.52,95%CI 0.33-0.83,P=.01)。
- 无症状型烟雾病:搭桥手术与死亡风险降低相关(AHR 0.74,95%CI 0.66-0.84,P<.001),但与出血性卒中风险增加相关(AHR 1.76,95%CI 1.56-2.00,P<.001)。
- 分层分析:<55岁缺血型搭桥与死亡风险降低相关(AHR 0.34,95%CI 0.13-0.88,P=.03),<55岁无症状型搭桥与死亡风险降低相关(AHR 0.69,95%CI 0.60-0.79,P<.001)。
- ≥55岁缺血型烟雾病搭桥与出血性卒中风险增加相关(AHR 2.13,95%CI 1.1-4.16,P=.03)。
适用人群与场景
- 成人(年龄≥15岁)烟雾病患者,数据来自韩国国民健康保险研究数据库,诊断时间2008年1月1日至2020年12月31日,随访至2021年12月31日。
- 共纳入19700例,其中出血型3194例、缺血型517例、无症状型15989例;平均(SD)年龄45.43(14.98)岁,女性12766例(64.8%)。
研究设计与关键结果
- 研究设计:回顾性、全国、人群基础的纵向队列研究,比较搭桥手术(直接或间接)与保守治疗的结局,主要终点为死亡,次要终点为出血性卒中或缺血性卒中。
- 出血型烟雾病:搭桥手术与死亡风险降低相关(AHR 0.50,95%CI 0.41-0.61,P<.001),与出血性卒中风险降低相关(AHR 0.36,95%CI 0.30-0.40,P<.001)。
- 缺血型烟雾病:搭桥手术与缺血性卒中风险降低相关(AHR 0.55,95%CI 0.37-0.81,P=.002)。
- 无症状型烟雾病:搭桥手术与死亡风险降低相关(AHR 0.74,95%CI 0.66-0.84,P<.001),与出血性卒中风险增加相关(AHR 1.76,95%CI 1.56-2.00,P<.001)。
- 在出血型和无症状型烟雾病中,直接搭桥与间接搭桥效果相似;在缺血型烟雾病中,仅直接搭桥与缺血性卒中风险降低相关(AHR 0.52,95%CI 0.33-0.83,P=.01)。
- 分层分析:<55岁缺血型患者搭桥与死亡风险降低相关(AHR 0.34,95%CI 0.13-0.88,P=.03);<55岁无症状型患者搭桥与死亡风险降低相关(AHR 0.69,95%CI 0.60-0.79,P<.001);≥55岁缺血型患者搭桥与出血性卒中风险增加相关(AHR 2.13,95%CI 1.1-4.16,P=.03)。
证据类型、等级与局限
- 证据类型:回顾性、全国、人群基础的纵向队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,成人烟雾病患者的管理策略应依据起病类型(无症状、缺血、出血)进行个体化制定;本研究结果提示搭桥手术在不同起病类型中与不同结局相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Moyamoya disease (MMD) is a rare chronic cerebrovascular disease, and the outcomes of bypass management in adult patients remain controversial.
OBJECTIVE: To categorize adult MMD based on asymptomatic, ischemic, and hemorrhagic onset and compare the outcomes (death, hemorrhagic stroke [HS], and ischemic stroke [IS]) of bypass surgery (direct or indirect) with those of conservative management.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective, nationwide, population-based longitudinal cohort study used Korean National Health Insurance Research data to identify adults (aged ≥15 years) with MMD who were diagnosed between January 1, 2008, and December 31, 2020, and followed up until December 31, 2021 (median follow-up, 5.74 [IQR, 2.95-9.42] years). A total of 19 700 participants (3194 with hemorrhagic, 517 with ischemic, and 15 989 with asymptomatic MMD) were included. Data were analyzed from January 2 to April 1, 2023.
EXPOSURES: Bypass surgery and conservative management.
MAIN OUTCOMES AND MEASURES: Death constituted the primary outcome; secondary outcomes consisted of HS or IS. Kaplan-Meier survival curve and Cox proportional hazards regression analysis were applied. The propensity score-matching and stratified analyses were performed to control covariate effects.
RESULTS: A total of 19 700 patients (mean [SD] age, 45.43 [14.98] years; 12 766 [64.8%] female) were included. Compared with conservative management, bypass was associated with a reduced risk of death (adjusted hazard ratio [AHR], 0.50 [95% CI, 0.41-0.61]; P < .001) and HS (AHR, 0.36 [0.30-0.40]; P < .001) in hemorrhagic MMD; reduced risk of IS (AHR, 0.55 [95% CI, 0.37-0.81]; P = .002) in ischemic MMD; and reduced risk of death (AHR, 0.74 [95% CI, 0.66-0.84]; P < .001) in asymptomatic MMD. However, bypass was associated with an increased risk of HS (AHR, 1.76 [95% CI, 1.56-2.00]; P < .001) in asymptomatic MMD. Both direct and indirect bypass demonstrated similar effects in hemorrhagic and asymptomatic MMD, except only direct bypass was associated with a reduced risk of IS (AHR, 0.52 [95% CI, 0.33- 0.83]; P = .01) in ischemic MMD. After stratification, bypass was associated with a reduced risk of death in patients younger than 55 years with ischemic (AHR, 0.34 [95% CI, 0.13- 0.88]; P = .03) and asymptomatic (AHR, 0.69 [95% CI, 0.60-0.79]; P < .001) MMD, but an increased risk of HS in patients 55 years or older with ischemic MMD (AHR, 2.13 [95% CI, 1.1-4.16]; P = .03).
CONCLUSIONS AND RELEVANCE: The findings of this cohort study of bypass outcomes for patients with MMD emphasize the importance of tailoring management strategies in adult patients based on onset types.
参考来源
- Lim YC, Lee E, Song J, et al. Outcomes of Bypass Surgery in Adult Moyamoya Disease by Onset Type. JAMA Netw Open. 2024. PMID: 38842810. doi:10.1001/jamanetworkopen.2024.15102
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。